Small Molecules

28 Jul 2021 U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)
28 Jul 2021 Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
28 Jul 2021 HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
28 Jul 2021 BridgeBio Announces Clinical Collaboration with Bristol Myers Squibb to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with OPDIVO® (nivolumab) in Advanced Solid Tumors with KRAS Mutations
28 Jul 2021 Grünenthal's Glucocorticoid Receptor Modulator enters clinical development
28 Jul 2021 Kintor Pharmaceutical Announces Dosing of First Batch of Subjects in Phase I Clinical Trial of GT20029 in China
28 Jul 2021 Eccogene Announces Completed First-in-human of ECC0509 in Phase 1a Clinical Trial in Australia
28 Jul 2021 Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer (TNBC)
27 Jul 2021 Iterum Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Oral Sulopenem
26 Jul 2021 New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition
24 Jul 2021 Tonix Pharmaceuticals Announces Outcome of Interim Analysis of Phase 3 RALLY Study of TNX-102 SL for the Management of Fibromyalgia
23 Jul 2021 HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)
22 Jul 2021 Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
22 Jul 2021 Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML
22 Jul 2021 VERQUVO® (vericiguat) Approved in the European Union
22 Jul 2021 IM Therapeutics Reports Positive Results in Safety, Tolerability and Mechanism of Action of Phase 1b Trial of Lead Drug IMT-002 in Type 1 Diabetes
21 Jul 2021 NIMIUM Therapeutics and Paraza Pharma form partnership to develop new medicines to treat cardiometabolic diseases (CMDs), obesity and type 2 diabetes
21 Jul 2021 FDA Grants Breakthrough Therapy Designation for Venclexta in Combination With Azacitidine for the Treatment of Patients With Myelodysplastic Syndromes
20 Jul 2021 Frontier Medicines Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline
20 Jul 2021 Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive Familial Intrahepatic Cholestasis (PFIC)
20 Jul 2021 Elucida Oncology Submits IND Application for ELU-001 for the Treatment of Cancers Overexpressing Folate-Receptor Alpha
20 Jul 2021 Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids
20 Jul 2021 Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program
20 Jul 2021 Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184
20 Jul 2021 Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up